Showing results (41-50 of 93) with videos related to

Sort By:
Pageof 10
Thoracic Cancer|April 8, 2022
Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non-small cell lung cancerHisao Imai, Erika Naito, Ou Yamaguchi, et al.
Cancer Immunology, Immunotherapy : CII|July 12, 2025
Correlation between T cell immunity and the duration of EGFR-TKI resistance acquisition in patients harboring EGFR mutationsAtsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, et al.
Thoracic Cancer|August 22, 2023
Clinicopathological impact of VEGFR2 and VEGF-C in patients with EGFR-major mutant NSCLC receiving osimertinibKyoichi Kaira, Hisao Imai, Atsuto Mouri, et al.
BMC Cancer|March 2, 2021
A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027Yuji Minegishi, Ou Yamaguchi, Shunichi Sugawara, et al.
Thoracic Cancer|February 24, 2021
Clinical impact of post-progression survival on overall survival in patients receiving nivolumab monotherapy as a second-line treatment for advanced non-small cell lung cancerHisao Imai, Ou Yamaguchi, Keita Mori, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|April 30, 2023
[Thoracic SMARCA4-deficient undifferentiated tumor resembling malignant lymphoma]Chie Asou, Tomoya Maeda, Ou Yamaguchi, et al.
Scientific Reports|October 10, 2025
Prognostic relevance of TROP2 expression in patients with non-small cell lung cancer receiving immunotherapyNaohito Hashimoto, Shota Takei, Kyoichi Kaira, et al.
Current Oncology (Toronto, Ont.)|March 27, 2026
Concurrent Chemoradiotherapy with Daily Low-Dose Carboplatin in Older Patients with Unresectable Locally Advanced Non-Small-Cell Lung Cancer: Clinical Outcomes and Prognostic Significance of Systemic Inflammation MarkersYu Miura, Hisao Imai, Satoshi Endo, et al.
Journal of Thoracic Disease|April 16, 2026
Prognostic value as metabolic tumor activity on 18F-FDG uptake in thymic epithelial tumorsKosuke Hashimoto, Kyoichi Kaira, Hisao Imai, et al.
Oncology Letters|February 23, 2023
Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancerTakeshi Tsuda, Hisao Imai, Yoshiaki Nagai, et al.
Pageof 10